333 related articles for article (PubMed ID: 28085016)
21. Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential.
van de Ven K; Borst J
Immunotherapy; 2015; 7(6):655-67. PubMed ID: 26098609
[TBL] [Abstract][Full Text] [Related]
22. OX40/OX40 ligand and its role in precision immune oncology.
Thapa B; Kato S; Nishizaki D; Miyashita H; Lee S; Nesline MK; Previs RA; Conroy JM; DePietro P; Pabla S; Kurzrock R
Cancer Metastasis Rev; 2024 Mar; ():. PubMed ID: 38526805
[TBL] [Abstract][Full Text] [Related]
23. Co-stimulatory molecules in and beyond co-stimulation - tipping the balance in atherosclerosis?
Gerdes N; Zirlik A
Thromb Haemost; 2011 Nov; 106(5):804-13. PubMed ID: 21979444
[TBL] [Abstract][Full Text] [Related]
24. Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy.
Liu G; Luo P
Front Immunol; 2023; 14():1208788. PubMed ID: 37334375
[TBL] [Abstract][Full Text] [Related]
25. The contextual role of TNFR family members in CD8(+) T-cell control of viral infections.
Wortzman ME; Clouthier DL; McPherson AJ; Lin GH; Watts TH
Immunol Rev; 2013 Sep; 255(1):125-48. PubMed ID: 23947352
[TBL] [Abstract][Full Text] [Related]
26. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
Lynch DH
Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
[TBL] [Abstract][Full Text] [Related]
27. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB
Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282
[TBL] [Abstract][Full Text] [Related]
28. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice.
Cuadros C; Dominguez AL; Lollini PL; Croft M; Mittler RS; Borgström P; Lustgarten J
Int J Cancer; 2005 Oct; 116(6):934-43. PubMed ID: 15856473
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy targeting 4-1BB and its ligand.
Vinay DS; Kwon BS
Int J Hematol; 2006 Jan; 83(1):23-8. PubMed ID: 16443548
[TBL] [Abstract][Full Text] [Related]
30. CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs.
Zapata JM; Perez-Chacon G; Carr-Baena P; Martinez-Forero I; Azpilikueta A; Otano I; Melero I
Front Immunol; 2018; 9():2618. PubMed ID: 30524423
[TBL] [Abstract][Full Text] [Related]
31. Contribution of CD30/CD153 but not of CD27/CD70, CD134/OX40L, or CD137/4-1BBL to the optimal induction of protective immunity to Mycobacterium avium.
Flórido M; Borges M; Yagita H; Appelberg R
J Leukoc Biol; 2004 Nov; 76(5):1039-46. PubMed ID: 15316035
[TBL] [Abstract][Full Text] [Related]
32. Neoantigens in the immuno-oncology space.
Arlen PM
Future Oncol; 2017 Oct; 13(25):2209-2211. PubMed ID: 28976211
[No Abstract] [Full Text] [Related]
33. Rationale for anti-OX40 cancer immunotherapy.
Aspeslagh S; Postel-Vinay S; Rusakiewicz S; Soria JC; Zitvogel L; Marabelle A
Eur J Cancer; 2016 Jan; 52():50-66. PubMed ID: 26645943
[TBL] [Abstract][Full Text] [Related]
34. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.
Sanchez-Paulete AR; Labiano S; Rodriguez-Ruiz ME; Azpilikueta A; Etxeberria I; Bolaños E; Lang V; Rodriguez M; Aznar MA; Jure-Kunkel M; Melero I
Eur J Immunol; 2016 Mar; 46(3):513-22. PubMed ID: 26773716
[TBL] [Abstract][Full Text] [Related]
35. GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily.
Nocentini G; Riccardi C
Eur J Immunol; 2005 Apr; 35(4):1016-22. PubMed ID: 15770698
[TBL] [Abstract][Full Text] [Related]
36. Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.
Bulliard Y; Jolicoeur R; Windman M; Rue SM; Ettenberg S; Knee DA; Wilson NS; Dranoff G; Brogdon JL
J Exp Med; 2013 Aug; 210(9):1685-93. PubMed ID: 23897982
[TBL] [Abstract][Full Text] [Related]
37. Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens.
Waight JD; Chand D; Dietrich S; Gombos R; Horn T; Gonzalez AM; Manrique M; Swiech L; Morin B; Brittsan C; Tanne A; Akpeng B; Croker BA; Buell JS; Stein R; Savitsky DA; Wilson NS
Cancer Cell; 2018 Jun; 33(6):1033-1047.e5. PubMed ID: 29894690
[TBL] [Abstract][Full Text] [Related]
38. An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer.
Chu DT; Bac ND; Nguyen KH; Tien NLB; Thanh VV; Nga VT; Ngoc VTN; Anh Dao DT; Hoan LN; Hung NP; Trung Thu NT; Pham VH; Vu LN; Pham TAV; Thimiri Govinda Raj DB
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013788
[TBL] [Abstract][Full Text] [Related]
39. Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy-Focus on FcγRIIB.
Teige I; Mårtensson L; Frendéus BL
Front Immunol; 2019; 10():481. PubMed ID: 30930905
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic potential of 4-1BB (CD137) as a regulator for effector CD8(+) T cells.
Kim YJ; Broxmeyer HE
J Hematother Stem Cell Res; 2001 Aug; 10(4):441-9. PubMed ID: 11522228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
